Navigation Links
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
Date:8/20/2007

The article is available online at http://bloodjournal.hematologylibrary.org/cgi/content/abstract/blood-2007-0 6- 095646v1. The analysis will also be published in a future print edition of Blood.

About PNH

PNH is an acquired genetic blood disorder defined by hemolysis, in which patients' red blood cells are destroyed by complement, a component of the body's immune system. PNH is a rare disease that affects an estimated 8,000 to 10,000 people in North America and Europe.(13) PNH often strikes people in the prime of their lives, with an average age of onset in the early 30's.(3) Approximately ten percent of all patients first develop symptoms at 21 years of age or younger.(2) PNH develops without warning and can occur in men and women of all races, backgrounds and ages. PNH often goes unrecognized, with delays in diagnosis often ranging from one to more than 10 years.(4) The estimated median survival for PNH patients is between 10 and 15 years from the time of diagnosis.(13,4)

PNH has been identified more commonly among patients with disorders of the bone marrow, including aplastic anemia (AA) and myelodysplastic syndrome (MDS).(14,15,16,17) In patients with thrombosis of unknown origin, PNH may be an underlying cause.(2,18)

Prior to approval of Soliris, there were no therapies specifically available for the treatment of PNH. PNH treatment was limited to symptom management through periodic blood transfusions, non-specific immunosuppressive therapy and, infrequently, bone marrow transplantations -- a procedure that carries considerable mortality risk.(2,18)

About Soliris

Soliris was approved in March 2007 by the U.S. Food and Drug Administration (FDA) as the first treatment for PNH, a rare, debilitating and life-threatening blood disorder defined by hemolysis, or the destruction of red blood cells. In June 2007, the European Commi
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
2. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
7. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
8. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
9. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
10. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
11. Skin Rash Actually Signifies Better Outcomes for Pancreatic and Lung Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... LA HABRA, Calif. , May 1, 2015 /PRNewswire-USNewswire/ ... to announce its 2015 health literacy award winners. The ... reward initiatives that make an impact on the practice ... that advance health literacy. IHA gives awards in three ... IHA also bestowed its Health Literacy Hero award. ...
(Date:5/1/2015)... 1, 2015 Semler Scientific, Inc. (Nasdaq: ... develops, manufactures and markets products that assist healthcare providers ... financial results for the first quarter ended March 31, ... 2015, Semler reported continued progress with year over year ... growth of 14%," said Doug Murphy-Chutorian , M.D., ...
(Date:5/1/2015)... NEW YORK , May 1, 2015  Shares ... over 70% of their value yesterday following the results ... company,s glaucoma therapy, Rhopressa.  Despite the trial failing to ... indicates that positive results may come from future studies. ... a brief company overview, current pipeline, financial review, analyst ...
Breaking Medicine Technology:Institute for Healthcare Advancement Announces 2015 Award Winners 2Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2
... 12, 2011 Reportlinker.com announces that a new ... Global Injectable Drug Delivery Market ... Report Description : ... * To define and measure the Injectable drug ...
... BOSTON, Oct. 12, 2011 PAREXEL International Corporation ... biopharmaceutical services provider, today announced that it has ... topics throughout the clinical development and commercialization lifecycle. ... are conversations with thought leaders from PAREXEL designed ...
Cached Medicine Technology:Global Injectable Drug Delivery Market (2010 - 2015) 2Global Injectable Drug Delivery Market (2010 - 2015) 3Global Injectable Drug Delivery Market (2010 - 2015) 4Global Injectable Drug Delivery Market (2010 - 2015) 5Global Injectable Drug Delivery Market (2010 - 2015) 6Global Injectable Drug Delivery Market (2010 - 2015) 7Global Injectable Drug Delivery Market (2010 - 2015) 8Global Injectable Drug Delivery Market (2010 - 2015) 9Global Injectable Drug Delivery Market (2010 - 2015) 10Global Injectable Drug Delivery Market (2010 - 2015) 11Global Injectable Drug Delivery Market (2010 - 2015) 12New PAREXEL Podcast Series to Deliver Clinical Development and Commercialization Thought Leadership 2New PAREXEL Podcast Series to Deliver Clinical Development and Commercialization Thought Leadership 3New PAREXEL Podcast Series to Deliver Clinical Development and Commercialization Thought Leadership 4
(Date:5/3/2015)... 03, 2015 Looking for a ... directly impact your career? The Master of International ... leaders in multinational companies and for professionals seeking ... changing global landscape, differences in culture, religion, government, ... EMIB program develops the global competence and confidence ...
(Date:5/3/2015)... 2015 SpineFrontier, a Less Exposure Surgery ... to produce and market their new sacroiliac joint fusion ... in outpatient settings and is compatible with both lateral ... has been extensively researched and refined by SpineFrontier, the ... this approach in conjunction with a sacroiliac joint fusion ...
(Date:5/3/2015)... 2015 HealthPostures, a pioneering ergonomics ... its appearance at the , May 5 - 7, ... will exhibit at the conference include its bestselling TaskMate ... solutions is the 6100 TaskMate Executive. Features of the ... adjustable keyboard tray, extended platform work surface and supply ...
(Date:5/2/2015)... NV (PRWEB) May 02, 2015 Ticket Down ... tickets for the long awaited event today, Saturday, May ... Diehard boxing fans will be able to secure tickets ... , The fight that boxing fans have wanted for more ... months ago. Floyd “Money” Mayweather will step inside the ring ...
(Date:5/2/2015)... ActOn ” was featured on NewsWatch as part of its ... coolest applications on the market for iOS, Android, and Windows. ... the app review and shared with viewers how this app ... difference. , In this material world, almost everything is about ... which is why those things should be prioritized above others. ...
Breaking Medicine News(10 mins):Health News:The Saint Louis University's Master of International Business Is Now Enrolling For Fall 2015 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 2Health News:HealthPostures to Appear at the Minnesota Safety and Health Conference 3Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:An Application to Help People Make a Difference Was Featured on NewsWatch Television 2
... who were treated with anti-tumor necrosis factor alpha, ... exacerbations than individuals taking a placebo. ,This ... 2006 of the American Journal of Respiratory and ... Society. ,Trevor T. Hansel, M.D., Ph.D., ...
... care in United Kingdom, and a munificent grant of ?45 ... figure anywhere on the NHS dental list. , ,The ... NHS registrations, down by a 42000 enrollments. This, notwithstanding the ... to ensure registrations are maintained. Yet, it has not made ...
... professor says that laws, which require minors to seek ... sexual behavior// in this segment of the society. Jonathan ... Thomas Stratmann, professor of economics at George Mason University ... laws seeking parental consent may play an important role. ...
... developed a prototype bandage that could detect hidden fractures once ... by Ozan Akkus and colleagues at Purdue University in Indiana ... created by tiny cracks in damaged bones, reported the online ... alarm, warning the patient to rest so that the injured ...
... capital has recorded 327 cases of dengue fever this year so ... ,According to health authorities here, two more people have died ... nine. ,Out of the 327 cases reported, 127 cases ... that the next two months is likely to see a surge ...
... The directory of patented drugs will play host to a ... to the recent communique // by the Director of patent ... in the arm for the multitude of generic drug manufacturers, ... the drug to developing nations. ,Biolyse ...
Cached Medicine News:Health News:Monoclonal Antibody Reduces Exacerbations in Asthmatics 2Health News:Laws That Make Parental Consent Mandatory Reduce Risky Sexual Behavior 2
8 mm S Graftech cervical spacer....
... system for procedures in the ... system features a broad selection ... for many Craniomaxillofacial procedures. 1.5 ... used predominately in the less ...
A unique system for secure fixation of the cranial bone flap after craniotomy. Craniofix eliminates the need for mini plates, screws, and additional drills....
... Timesh 1.5 Titanium Cranial Fixation Systems ... benefits specifically requested by surgeons and ... cranioplasty implants may be either shaped ... procedure warrants, a pre-measured, cut, bent ...
Medicine Products: